A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011

Maria Jesus del Cerro1, Steven Abman2, Gabriel Diaz3, Alexandra Heath Freudenthal4, Franz Freudenthal4, S. Harikrishnan1, Sheila G. Haworth6, Dunbar Ivy7, Antonio A. Lopes7, J. Usha Raj8, Julio Sandoval5, Kurt Stenmark2, and Ian Adatia10

1La Paz Children’s Hospital, Madrid, Spain, 2Children’s Hospital, University of Colorado School of Medicine, Aurora, Colorado, USA, 3Universidad Nacional de Colombia, Bogotá, Colombia, 4Kardiozentrum, La Paz, Bolivia, 5Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, India, 6University College, London, UK, 7Heart Institute, University of São Paulo, São Paulo, Brazil, 8University of Chicago at Illinois, Chicago, USA, 9National Institute of Cardiology, Mexico City, Mexico, 10Stollery Children’s Hospital, University of Alberta, Edmonton, Alberta, Canada

ABSTRACT

Current classifications of pulmonary hypertension have contributed a great deal to our understanding of pulmonary vascular disease, facilitated drug trials, and improved our understanding of congenital heart disease in adult survivors. However, these classifications are not applicable readily to pediatric disease. The classification system that we propose is based firmly in clinical practice. The specific aims of this new system are to improve diagnostic strategies, to promote appropriate clinical investigation, to improve our understanding of disease pathogenesis, physiology and epidemiology, and to guide the development of human disease models in laboratory and animal studies. It should be also an educational resource. We emphasize the concepts of perinatal maladaptation, maldevelopment and pulmonary hypoplasia as causative factors in pediatric pulmonary hypertension. We highlight the importance of genetic, chromosomal and multiple congenital malformation syndromes in the presentation of pediatric pulmonary hypertension. We divide pediatric pulmonary hypertensive vascular disease into 10 broad categories.

Key Words: pulmonary hypertension, pulmonary hypertension in the newborn, pulmonary vascular disease, pediatric patient

INTRODUCTION

The classification of pulmonary hypertension conceived at the 1998 WHO Symposium in Evian11 and the subsequent revisions and refinements that resulted from symposia in Venice12 and Dana Point13 have contributed greatly to the understanding of pulmonary vascular disease, facilitated drug trials and improved our understanding of congenital heart disease in adult survivors. However, these classifications are not applicable readily to pediatric disease.14-7 The response to the debate on the classification of pediatric pulmonary hypertension at the Pulmonary Vascular Research Institute (PVRI) meeting in Lisbon in 2010 suggested that there was a widespread, well-recognized need for the development of a classification system of pediatric pulmonary hypertensive vascular disease specifically for use in children. Also, it was recognized that physicians, who care for adult survivors of pediatric disease, might be able also to use such a classification in their assessments. As a result, the PVRI Pediatric Taskforce was initiated. This paper summarizes the work of the PVRI Pediatric Taskforce as presented at the 2011 annual meeting of the PVRI in Panama.
DISCUSSION

Difficulties in applying the Dana Point Classification to pediatrics

The areas of particular difficulty in applying the Dana Point Classification in pediatrics are mentioned briefly here and expanded upon under specific headings later in the article. The fetal origins of pulmonary vascular disease are important not only in pediatric diseases, but also in adults as perinatal events are likely to play a key role in establishing the risk for pulmonary hypertension. The Dana Point Classification does not acknowledge the potential importance of developmental mechanisms. Pulmonary hypertensive vascular disease, even when presenting in adulthood, maybe related to fetal, perinatal and early childhood development. The perinatal origins of systemic hypertension and coronary artery disease in adults are now well recognized. Neonatal pulmonary vascular disease received inconsistent attention at Evian, Venice and Dana Point. In particular the concepts of perinatal maladaptation, maldevelopment and pulmonary hypoplasia as causative factors in neonatal pulmonary hypertension were not listed. Furthermore as a tool in the real life clinical assessment of the young child, the Dana Point Classification often does not reflect the complex heterogeneity of factors that contribute to pediatric pulmonary vascular disease (Fig. 1). For instance in pediatric practice, patients are commonly evaluated for pulmonary hypertension who may have been born prematurely, with chromosomal or genetic anomalies, congenital cardiac defects, as well as, sleep disordered breathing, chronic aspiration and secondary parenchymal pulmonary disease.

Aims of the PVRI Panama Classification

The classification system that we propose is based firmly in clinical practice. The specific aims of this new system are to improve diagnostic strategies, to promote appropriate clinical investigation and to improve our understanding of disease pathogenesis, physiology and epidemiology and to guide the development of human disease models in laboratory and animal studies. It should also be an educational resource. This classification system unequivocally is not based on therapy of pulmonary hypertension or designed to be a therapeutic guide. The utility of an effective classification system lies in its ability to help us to make sense of our observations on each child, but be structured enough to permit unambiguous classification when possible but flexible enough to allow for the inclusion of as yet undiscovered ideas. Classifications are useful in medicine if they provide a framework for the diagnosis and management of a disease, and encourage epidemiological insight. A perfect classification, like the periodic table, would also have categories for as yet undiscovered disease or mechanisms of known disease complexes.

We acknowledge the great value of the Dana Point Classification. Indeed, there are elements that we have left untouched. We are cognizant that if our suggested classification system has any merit it is because— to paraphrase Sir Isaac Newton in 1676— only by “standing on the shoulders of giants” have we been able to see further. With this in mind, we propose a new classification of pediatric pulmonary hypertensive vascular disease.

Overall schema

We have used the term pediatric pulmonary hypertensive vascular disease in preference to pulmonary hypertension to exclude patients with pulmonary hypertension but without an elevated pulmonary vascular resistance (Table 1). This occurs in children with large systemic to pulmonary connections. These children do not require drug therapy for pulmonary hypertension but rather benefit from timely and accurate closure of the defect. We do, however, wish to include children who have undergone various stages of single ventricle treatment who may have a symptomatically elevated pulmonary vascular resistance but with a mean pulmonary artery pressure <25 mmHg. Thus we suggest that pediatric pulmonary hypertensive vascular disease be defined as a mean pulmonary artery pressure >25 mmHg and a pulmonary vascular resistance index >3.0 Wood units m² for biventricular circulations. We suggest that pulmonary hypertensive vascular disease following a cavopulmonary anastomosis be defined as a pulmonary vascular resistance index >3.0 Wood units m² or a transpulmonary gradient >6 mmHg (mean pulmonary artery pressure minus mean left atrial pressure) even if the mean pulmonary artery pressure is <25 mmHg. We add the caveat that calculated pulmonary vascular resistance maybe increased, not only, by an increased transpulmonary gradient, but also, by decreased pulmonary blood flow. We acknowledge that...
pulmonary blood flow maybe difficult to estimate after a cavopulmonary anastomosis because of multiple sources of pulmonary blood flow.

The pulmonary artery occlusion, left atrial or systemic ventricular end diastolic pressures maybe increased or normal but these values are clearly important in considering the differential diagnosis.

We have divided pediatric pulmonary hypertensive vascular disease into 10 broad categories listed in order of frequency of presentation to the pediatric clinic (Table 1). There is no published all-inclusive epidemiological study or registry data on pediatric pulmonary hypertension. As far as we can tell the reports to date have excluded one or other of the categories in the classification system we present here. Therefore, when such data is available the order of the categories may need revision. We emphasize that we have attempted to provide a clinically useful classification (Table 2), which permits the categorization of patients with multifactorial causes of pulmonary hypertension especially when associated with a syndrome or chromosomal abnormality. To reflect the heterogeneity of pulmonary vascular disease in childhood we have included the possibility that a disease or condition may appear in different categories. This is particularly the case when a disease such as sickle cell, scimitar or antiphospholipid syndrome may cause different types of pulmonary hypertensive vascular disease.

**CATEGORY 1**

**Prenatal or developmental pulmonary vascular disease**

Perhaps the most striking difference between the adult and childhood onset of pulmonary hypertensive vascular disease is that during fetal, neonatal and early postnatal life the pulmonary vasculature is exposed to pathological and/or environmental insults while it is still growing and maturing. This may result in maladaptation, maldevelopment or growth arrest. Natural attempts at recovery from insults may be influenced by the ongoing developmental and maturational signals. This may result in unique and different sequelae than those seen in adults exposed to a similar insult (Table 2). The lung-vascular unit is composed of alveolus, bronchiole, capillary, arteriole, venule and lymphatic channel and the development of each is dependent upon another.[9] Disease of one element in the lung-vascular unit may affect other components as for example in persistent pulmonary hypertension of the newborn, bronchopulmonary dysplasia[10] (Fig. 2) and alveolar capillary dysplasia with misalignment of the pulmonary veins.[11]

**Table 1: The broad schema of 10 basic categories of Pediatric Pulmonary Hypertensive Vascular Disease**

| Category | Description |
|----------|-------------|
| 1        | Prenatal or developmental pulmonary hypertensive vascular disease |
| 2        | Perinatal pulmonary vascular maladaptation |
| 3        | Pediatric cardiovascular disease |
| 4        | Bronchopulmonary dysplasia |
| 5        | Isolated pediatric pulmonary hypertensive vascular disease (isolated pediatric PAH) |
| 6        | Multifactorial pulmonary hypertensive vascular disease in congenital malformation syndromes |
| 7        | Pediatric lung disease |
| 8        | Pediatric thromboembolic disease |
| 9        | Pediatric hypobaric hypoxic exposure |
| 10       | Pediatric pulmonary vascular disease associated with other system disorders |
Table 2: Detailed Classification of pediatric pulmonary hypertensive vascular disease

1. Prenatal or developmental pulmonary hypertensive vascular disease
1.1. Associated with maternal or placental abnormalities
   1.1.1 Pre-eclampsia
   1.1.2 Chorioamnionitis
   1.1.3 Maternal drug ingestion (Nonsteroidal anti inflammatory drugs)\(^{[158-165]}\)
1.2. Associated with fetal pulmonary vascular maldevelopment
   1.2.1. Associated with Fetal Pulmonary Hypoplasia
      1.2.1.a. Idiopathic pulmonary hypoplasia
      1.2.1.b. Familial pulmonary hypoplasia
      1.2.1.c. Congenital diaphragmatic hernia
      1.2.1.d. Hepatopulmonary fusion
      1.2.1.e. Scimitar syndrome
      1.2.1.f. Associated with fetal pulmonary compression
               oligohydramnios
               omphalocele/gastroschisis
               cystic adenomatosis
               fetal tumours or masses
      1.2.1.g. Associated with fetal skeletal malformations
   1.2.2. Associated with Fetal Lung Growth Arrest/Maldevelopment
      1.2.2.a. Acinar dysplasia
      1.2.2.b. Congenital alveolar dysplasia
      1.2.2.c. Alveolar capillary dysplasia with/out misalignment of pulmonary veins
      1.2.2.d. Lymphangiectasia
      1.2.2.e. Pulmonary artery abnormalities
      1.2.2.f. Pulmonary venous abnormalities

1.3. Associated with fetal cardiac maldevelopment
   1.3.1. Premature closure of foramen ovale or ductus arteriosus
      1.3.1.a. Idiopathic
      1.3.1.b. Drug induced
   1.3.2. Congenital heart defects associated/causing pulmonary vascular disease in the fetus
      1.3.2.a. Transposition of the great arteries (TGA) with intact ventricular septum
      1.3.2.b. Hypoplastic left heart syndrome with intact atrial septum
      1.3.2.c. Obstructed total anomalous pulmonary venous connection
      1.3.2.d. Common pulmonary vein atresia

2. Perinatal pulmonary vascular maladaptation (persistent pulmonary hypertension of the neonate, PPHN)
2.1. Idiopathic PPHN
2.2. PPHN associated with or triggered by
   2.2.1. Sepsis
   2.2.2. Meconium Aspiration
   2.2.3. Congenital heart disease
   2.2.4. Congenital diaphragmatic hernia
   2.2.5. Trisomy\(^{[13,18,21]}\)
   2.2.6. Drugs and Toxins
          Diazoxide

3. Pediatric heart disease
3.1. Systemic to pulmonary shunts
   3.1.1. PAH associated with systemic to pulmonary shunt with increased PVRI, no R-L shunt
      3.1.1.1. Operable
      3.1.1.2. Inoperable
   3.1.2. Classical Eisenmenger syndrome
      3.1.2.1. Eisenmenger–Simple lesion (ASD, VSD, PDA)
      3.1.2.2. Eisenmenger–Complex lesion (Truncus, TGA/VSD, single ventricle)
   3.1.3. Small defect with elevated pulmonary arterial pressure/PVRI out of proportion to the size of the defect
          Coexistent with inherited or idiopathic pulmonary hypertensive vascular disease

3.2. Post operative pulmonary arterial hypertension following
   3.2.1. Closure of shunt with
          3.2.1.1. persistent increase in PVRI>3 WU.m\(^2\)
          3.2.1.2. recurrent increase in PVRI>3 WU.m\(^2\)
   3.2.2. Arterial or atrial switch operation for TGA with intact ventricular septum
   3.2.3. Repair of left heart obstruction
3.2.4. Repair of tetralogy of Fallot
3.2.5. Repair of pulmonary atresia with VSD and MAPCA’s
3.2.6. Surgical aortopulmonary shunt

3.3. Pulmonary vascular disease following staged palliation for single ventricle physiology
   3.3.1. After stage 1 (PA banding, modified Norwood, Hybrid procedure, aortopulmonary or ventricular pulmonary shunt, stenting PDA)
   3.3.2. After SVC to PA anastomosis (Glenn)
   3.3.3. After total cavopulmonary anastomosis (Fontan)

3.4. Pediatric pulmonary hypertensive vascular disease associated with congenital abnormalities of the pulmonary arteries/veins
   3.4.1. PPHVD associated with congenital abnormalities of the pulmonary arteries
      3.4.1.1. Origin of a pulmonary artery from the aorta
      3.4.1.2. Unilateral isolation/ductal origin/"absence" of a pulmonary artery
   3.4.2. PPHVD associated with congenital abnormalities of the pulmonary veins
      3.4.2.1. Scimitar Complex
      3.4.2.2. Pulmonary vein stenosis
      3.4.2.3. Cantú syndrome[157]

3.5. Pulmonary venous hypertension
   3.5.1. Pulmonary venous hypertension due to congenital left heart inflow or outflow disease: aortic stenosis, aortic incompetence, mitral stenosis, mitral regurgitation, supramitral ring, pulmonary vein obstruction, cor triatriatum, endocardial fibroelastosis, left ventricular hypoplasia/Shone’s complex, congenital cardiomyopathy, restrictive atrial septum in hypoplastic left heart syndrome
   3.5.2. Pulmonary venous hypertension due to acquired left heart disease.
      Left sided Valvar Heart Disease (rheumatic/postendocarditis/rheumatoid arthritis)
      Restrictive /Dilated /Hypertrophic Cardiomyopathy
      Constrictive pericardial disease

4. Bronchopulmonary dysplasia
   4.1 with pulmonary vascular hypoplasia
   4.2 with pulmonary vein stenosis
   4.3 with left ventricular diastolic dysfunction
   4.4 with systemic to pulmonary shunts
      aortopulmonary collaterals
      arterial septal defect
      patent ductus arteriosus
      ventricular septal defect
   4.5. with significant hypercarbia and/or hypoxia

5. Isolated pediatric pulmonary hypertensive vascular disease (PPHVD) or isolated pulmonary arterial hypertension (PAH)
   5.1. Idiopathic PPHVD/Idiopathic PAH
   5.2. Inherited PPHVD/PAH
      5.2.1. BMPR2
      5.2.2. Alk 1, endoglin
      5.2.3. Unidentified genetic cause
   5.3. Drugs and Toxins
      5.3.1. Definite association: Toxic oil
      5.3.2. Likely association
         Amphetamine
      5.3.4. Possible association
         Cocaine
         Methylphenidate
         Diazoxide
         Cyclosporin
         Phenylpropanolamine
   5.4. Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis[156]
      5.4.1 Idiopathic PVOD
      5.4.2 Inherited PVOD

6. Multifactorial pulmonary hypertensive vascular disease associated with multiple congenital malformations/syndromes
   6.1. Syndromes with congenital heart disease
   6.2. Syndromes without congenital heart disease
      Both 6.1 and 6.2 may include- VACTERL, CHARGE, Poland, Adams-Oliver Syndrome, Scimitar complex, Trisomy, Di George, Noonan, Von Recklinghausen disease, Dursun syndrome, Cantú syndrome

7. Pediatric lung disease
   7.1. Cystic fibrosis
Table 2 continued

7.2. Interstitial lung diseases: surfactant protein deficiency etc.
7.3. Sleep disordered breathing
7.4. Chest wall and spinal deformities
7.5. Restrictive lung diseases
7.6. Chronic obstructive lung diseases

8. Pediatric thrombo-embolic disease causing pulmonary hypertensive vascular disease
8.1. Chronic thromboemboli from central venous catheters
8.2. Chronic thromboemboli from transvenous pacing wires
8.3. Ventriculo-atrial shunt for hydrocephalus
8.4. Sick cell disease
8.5. Primary endocardial fibroelastosis
8.6. Anticardiolipin/antiphospholipid syndrome
8.7. Methylmalonic acidemia and homocystinuria
8.8. Due to malignancy: osteosarcoma, Wilms tumor
8.9. Post splenectomy

9. Hypobaric hypoxic exposure
9.1. High altitude pulmonary edema (HAPE)
9.2. Infantile subacute mountain sickness
9.3. Monge disease
9.4. Hypobaric hypoxic exposure associated with PPHN
   Congenital heart disease
   Isolated PPHVD or PAH

10. Pulmonary hypertensive vascular disease associated with other system disorders
10.1. Pediatric portal hypertension
   10.1.1. Congenital extrahepatic portocaval/portosystemic shunt (e.g., Abernethy Syndrome, left atrial isomerism, trisomy21, portal vein atresia or thrombosis)
   10.1.2. Liver cirrhosis
10.2. Pediatric hematological disease
   10.2.1. Hemolytic anemias: beta-Thalassemia, sickle cell disease
   10.2.2. Post splenectomy
10.3. Pediatric oncological disease
   10.3.1. Pediatric pulmonary arterial hypertension associated with malignancy
   10.3.2. Pulmonary veno-occlusive disease after bone marrow transplantation and chemotherapy156
10.4. Pediatric metabolic/endocrine disease
   10.4.1. Gaucher disease
   10.4.2. Glycogen storage disease1,111
   10.4.3. Non ketotic hyperglycinemia
   10.4.4. Mitochondrial depletion syndrome
   10.4.5. Mucopolysaccharidosis
   10.4.6. Hypothyroidism/ Hyperthyroidism
10.5. Pediatric autoimmune or autoinflammatory disease
   10.5.1. POEMS
   10.5.2. Mixed connective tissue disease
   10.5.3. Scleroderma–limited and diffuse disease
   10.5.4. Dermatomyositis
   10.5.5. Systemic Lupus Erythematosus (SLE)
   10.5.6. Antiphospholipid/anticardiolipin syndrome
   10.5.7. Systemic-onset juvenile arthritis
   10.5.8 Pulmonary veno-occlusive disease and SLE156
10.6. Pediatric infectious disease
   10.6.1. Schistosomiasis
   10.6.2. HIV infection
   10.6.3. Pulmonary tuberculosis
10.7. Pediatric chronic renal failure
   10.7.1 Pulmonary arterial hypertension predialysis and with hemodialysis or peritoneal dialysis
   10.7.2 Pulmonary veno-occlusive disease after renal transplantation156
In utero, the fetal pulmonary circulation is characterized by high pulmonary artery pressure and markedly elevated pulmonary vascular resistance. In the first hours after birth, dramatic respiratory and circulatory events cause pulmonary vasodilation and favorable remodeling of the pulmonary vascular bed, which reduce pulmonary vascular resistance and lead to an increase in pulmonary blood flow. If successful transition of the pulmonary circulation occurs the pulmonary artery mean pressure decreases in the first three weeks of life to 10-20 mmHg, similar to adult levels. In young children total pulmonary vascular resistance indexed is similar to adults. Yet despite this physiological adaptation with reduction in pulmonary vascular resistance the ultra structural appearance of smooth muscle cells does not closely resemble that of the adult until about 2 years of age. Fetal growth factors may influence postnatal pulmonary vascular form and function.

It is clear that pediatric pulmonary hypertension specialists manage increasing numbers of neonates and children whose pulmonary hypertension may have fetal origins. In particular the association of pre-eclampsia and bronchopulmonary dysplasia, and disorders associated with lung hypoplasia and diseases associated with pulmonary vascular disease in utero. Pulmonary hypoplasia, the result of growth arrest, is an important concept in any classification system of neonatal pulmonary hypertensive disease. Pulmonary hypertensive vascular disease in children may occur against a background of varying degrees of pulmonary hypoplasia. This has been especially well documented particularly in congenital heart disease, congenital diaphragmatic hernia and Down syndrome. It is also relevant that alveolarisation and pulmonary vascular development may continue through the first 8 years of life. The normal rate of vascular growth and changes in the cross sectional area of the pulmonary vascular bed at birth or during the first years of life is unknown. Notably lung hypoplasia may be found in around 10% of neonatal autopsies and in up to 50% of neonates with congenital anomalies. It is possible that diverse postnatal pulmonary vascular insults, even those resulting in adult onset disease, are more likely to result in pulmonary hypertension if the subject was born with a pulmonary vascular cross sectional area below the 3rd percentile. Thus the likelihood of developing pulmonary hypertension throughout life may be related to the initial surface area at birth, with the effects of each successive insult at least partly due to the balance between pulmonary vascular reserve and rate of pulmonary vascular attrition due to the pathological insult be it genetic, epigenetic or environmental.

**CATEGORY 2**

**Perinatal pulmonary vascular maladaptation**

This category contains only the syndrome of persistent pulmonary hypertension of the newborn (PPHN). We recognize that there is considerable debate about the origins of PPHN and that it may reflect in utero pulmonary vascular disease. Clinical observations that neonates with severe PPHN who die during the first days after birth already have pathologic signs of chronic pulmonary vascular disease suggest that intrauterine events may play an important role in this syndrome. Adverse intrauterine stimuli during late gestation, such as abnormal blood flow, changes in substrate or hormone delivery to the lung, chronic hypoxia, chronic systemic hypertension, inflammation or others, may potentially alter lung vascular function and structure, contributing to abnormalities of postnatal adaptation. It seems likely that as the mechanisms of PPHN become understood better it will become necessary to reassess the classification. However, at present most would recognize PPHN as a disorder of transition from intra to extra uterine life.

Neonates born at high altitude frequently need more time to adapt to ex-utero life; some of them require supplementary oxygen for a few weeks. The pulmonary pressures remain increased above the normal age specific values for altitude, at this time. There is a delay in the pulmonary arterial remodeling after birth in those born at high altitude. However, we have acknowledged the considerable, even fatal effect that birth at very high altitudes (≥ 2,500m) may impose in the early postnatal period. These newer observations contrast with previous reports. We suggest that PPHN is a disease of the first 30 days of life that usually presents at, or within a few days, after birth. However, we recognize that it would be prudent to accelerate and broaden the diagnostic evaluation of any neonate presenting with symptomatic pulmonary hypertension outside the first week of life as the etiology may not be PPHN.

**CATEGORY 3**

**Pediatric cardiovascular disease**

Pediatric cardiovascular disease may be the most common disorder globally causing pulmonary vascular disease in children (Table 2).

The list of cardiac abnormalities and diseases is more comprehensive in this section of the classification than in the Dana Point Classification but we have maintained the basic structure of the Dana point classification as it pertains to shunts.
outcome of the diagnostic work up of a child with a shunt and elevated pulmonary vascular resistance index is to conclude whether or not the child should undergo cardiac repair or further evaluation. There is considerable interest in evaluating if a course of medical therapy will enable surgical repair in certain patients with borderline pulmonary vascular resistances.

The interaction between congenital heart disease and genetic factors often makes it difficult to classify the cause of the pulmonary hypertensive vascular disease with certainty. For instance how should a child with an atrioventricular canal defect and BMPR 2 mutation be classified? Or how should we classify a child with a minor cardiac shunt and a coexistent genetic or chromosomal anomaly? The classification allows for this eventuality and this area will become clarified in the future as we seek genetic links between congenital heart and pulmonary vascular disease.

Persistent or late presenting pulmonary vascular disease after atrial or arterial switch for transposition of the great arteries with an intact septum is recognized with such increasing frequency that we have specified the condition in the classification.

The classical Eisenmenger syndrome is well recognized as a multisystem disorder. However, the differentiation between complex and simple is clinically extremely important for both survival and functional level. Some studies have suggested that children with Eisenmenger may have a more rapid clinical decline than adults. There is growing concern that children with repaired congenital shunts and either persistent or recurrent pulmonary hypertension fare worse than patients with either Eisenmenger or idiopathic pulmonary hypertension. It is likely that this subgroup will need further refinement in the future.

The category entitled pulmonary venous hypertension includes in addition the cardiomyopathies, both acquired and congenital.

Pulmonary vascular disease following staged surgery for single ventricle: The use of pulmonary hypertension specific agents in the treatment of children and adults following the Glenn or Fontan type surgery is widespread. Preliminary data from the Spanish registry suggests that 14% of children receiving sildenafil or bosentan have a single ventricle type lesion. The interaction of the pulmonary and systemic circulations when the kinetic energy for blood flow through both circulations is derived from a single ventricular mass (and without a dedicated subpulmonary ventricle) is complex and pulmonary vascular resistance plays an important physiologic role. Recent studies have suggested that exercise intolerance, and even plastic bronchitis and protein losing enteropathy may be due in part to an increased pulmonary vascular resistance.

Hypobaric hypoxic exposure and congenital heart disease: We have included congenital heart disease at high altitude under Category 9 because high altitude may affect the incidence as well as the anatomy of the ductus arteriosus. This pertains also to children with trisomy 21 born at high altitude. In addition, pulmonary vascular reactivity testing (including prolonged hyperoxia testing) and management criteria may differ from those used at sea level.

**CATEGORY 4**

**Bronchopulmonary dysplasia**

Bronchopulmonary dysplasia (Table 2) remains the most common sequela after preterm birth, causing persistent cardiorespiratory problems throughout childhood and is growing as a significant problem in adulthood. Twelve percent (12%) of births are premature and place the patient at risk of bronchopulmonary dysplasia or chronic lung disease of prematurity. Bronchopulmonary dysplasia is a complex disorder and much more than chronic parenchymal lung disease secondary to ventilation strategies. Bronchopulmonary dysplasia, although it has changed over the decades, is characterized by an arrest of vascular and alveolar lung growth which often has prenatal origins. Thus a patient with bronchopulmonary dysplasia may have pulmonary hypertension due to decreased vascular growth compounded by intermittent or chronic hypoxia, hypercarbia due to lung and airway injury, a systemic to pulmonary shunt, diastolic cardiac dysfunction and pulmonary vein stenosis (Fig. 2).

**CATEGORY 5**

**Isolated pediatric pulmonary hypertensive vascular disease or isolated pediatric pulmonary arterial hypertension**

The category for isolated pulmonary hypertensive vascular disease or isolated pulmonary arterial hypertension (Table 2) resembles closely the Dana Point Classification. However, we suggest that the term “idiopathic” be reserved for those cases with truly “idiopathic” pulmonary hypertension i.e. unassociated with any other genetic, chromosomal etc. abnormality. In pediatrics the difficulties are encountered with a classification system if “idiopathic” pulmonary arterial hypertension is diagnosed together with a genetic defect or chromosomal syndrome.
Some drugs reported to cause pulmonary hypertension in children are different or (because they are used infrequently in pediatrics) less well validated from those described in adults. [87-92]

**CATEGORY 6**

**Multifactorial causes of pulmonary hypertension associated with congenital malformation syndromes**

We are recognizing more frequently that children born with congenital malformations (Table 2) often suffer from pulmonary vascular disease due to a number of contributing factors. Examples include CHARGE, VACTERL, Down syndrome and Di George spectrum of disorders. [23,93-106] In addition, pulmonary vascular disease secondary to a shunt maybe more rapidly progressive in patients with genetic syndromes. [107]

**CATEGORY 7**

**Pediatric lung disease**

The co-existence of certain lung diseases with pulmonary hypoplasia is recognized increasingly in children (Table 2). The classification of interstitial lung disease also suggests that lung hypoplasia and growth arrest are a common feature of a number of childhood interstitial lung diseases. [18] Pulmonary hypertension has a profound impact on the outcome of interstitial lung disease. [18] Genetic causes of lung disease are recognized and may have an impact on the prenatal pulmonary vasculature. [33,34,108,109]

**CATEGORY 8**

**Pediatric thromboembolic disease**

There is a lower incidence of pulmonary hypertension due to thromboembolic disease in children compared to adults. The associated or predisposing diseases associated with pulmonary thromboembolism in children are also in general different. [110-115] Although surgical options for chronic thromboembolic pulmonary hypertension have been explored less well in children, the success of surgical treatment of this disease in adults should encourage considering such an option in certain cases in the pediatric population (Table 2). [116,117]

**CATEGORY 9**

**Pediatric hypobaric hypoxic exposure**

Hypobaric hypoxic exposure or pulmonary hypertension due to high altitude (Table 2) was considered by those on the task force with extensive clinical experience working at high altitude to be sufficiently different from other forms of pulmonary arterial hypertension to justify inclusion as a separate category. These differences include hypoxia in the absence of parenchymal lung disease, different genetic aspects, and different treatment strategies. [4,44-46,70,72,118-126]

**CATEGORY 10**

**Pediatric pulmonary hypertensive vascular disease associated with other system disorders**

Here we have listed disorders (Table 2), which may be complicated by or associated with pulmonary hypertension. [100,127,148-155] We draw attention to unique aspects of pediatric disease such as extrahepatic portal hypertension, which may occur secondary to portal vein thrombosis following umbilical line placement and be overlooked as liver function tests may be normal.

**CONCLUSION**

We propose a comprehensive classification of pediatric pulmonary hypertension that includes pulmonary hypertensive disorders occurring throughout early life from the neonate to adolescent. We emphasize the importance of prenatal and perinatal influences, including maldevelopment and lung hypoplasia, that may contribute to pulmonary vascular disease. We suggest that pediatric pulmonary hypertensive vascular disease be defined as a mean pulmonary artery pressure >25 mmHg and a pulmonary vascular resistance index >3.0 Wood units m² for biventricular circulations. We suggest that following a cavopulmonary anastomosis pulmonary hypertensive vascular disease be defined as a pulmonary vascular resistance index >3.0 Wood units m² or a transpulmonary gradient >6 mmHg even if the mean pulmonary artery pressure is <25 mmHg. We have classified pediatric pulmonary hypertensive vascular disease into 10 broad categories. The classification we propose is based firmly on clinical practice. The specific aims are to improve diagnostic strategies, promote clinical investigation and understanding of pathogenesis, physiology and epidemiology, and to guide the development of human disease models in laboratory and animal studies. We hope, at the least, that this classification system will serve as a catalyst for improvement and lead ultimately to better outcomes for our patients. If there are omissions or improvements to be made, we encourage interested readers to let us know through the PVRI website (http://pvri.info/home).
REFERENCES

1. Rich S. Primary pulmonary hypertension: Executive summary from the world symposium-primary pulmonary hypertension 1998. Paper presented at: World Health Organisation, 1998; Evian.

2. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43 Suppl 12:S5-12.

3. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:543-54.

4. Diaz G. Aspectos Generales; Definición Clasificación y Epidemiología. In: Diaz G, Sandoval J, Sola A, editors. Hipertensión Pulmonar en Niños. Bogotá: Editorial Médica Distribúnia; 2011. p. 9-19.

5. van Albada ME, Berger RM. Pulmonary arterial hypertension in congenital cardiac disease—the need for refinement of the Evian-Venice classification. Cardiol Young 2008;18:10-7.

6. van Loon RL, Roofthoot MT, van Osch-Gevers M, Delhaas T, Stengers JL, Blom NA, et al. Clinical characterization of pediatric pulmonary hypertension: Complex presentation and diagnosis. J Pediatr 2009;155:176-82.e1.

7. Schulze-Neick I, Beghetti M. Classifying pulmonary hypertension in the setting of the congenitally malformed heart—cleaning up a dog’s dinner. Cardiol Young 2008;18:22-5.

8. Barker DJ. The developmental origins of adult disease. J Am Coll Nutr 2004;23 Suppl 6:588S-95.

9. Reid LM. Lung growth in health and disease. Br J Dis Chest 1984;78:113-34.

10. Abman SH. Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease. Adv Exp Med Biol 2010;661:323-35.

11. Eulmesekian P, Cutz E, Parvez B, Bohn D, Adatia I. Alveolar capillary dysplasia: A six-year single center experience. J Perinat Med 2005;33:37-52.

12. Rowe R, James L. The normal pulmonary arterial pressure during the first year of life. J Pediatr 1957;51:1-4.

13. Lock J, Einzig S, Moller J. Hemodynamic responses to exercise in normal children. Am J Cardiol 1978;41:1278-84.

14. Haworth SG. Persistent fetal circulation: Newly recognized structural features. J Pediatr 1976;88:613-19.

15. Shannon A, Sankaranarayanan K, Kinsella JP. Role of endothelin-derived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol 1990;259:H1921-7.

16. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:819-20.

17. Kinsella JP, Abman SH. Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn. J Pediatr 1995;126:853-64.

18. Abman SH, Chatfield BA, Hall SL, McMurray JF. Role of endothelium-derived relaxing factor in the development of bronchopulmonary dysplasia. J Pediatr 1995;126:853-64.

19. Han RN, Babaei S, Robb M, Lee T, Ridsdale R, Ackerley C, et al. Defective lung vascular development and fatal respiratory distress in endothelial NO synthase-deficient mice: A model of alveolar capillary dysplasia? Circ Res 2004;94:1115-23.

20. Kitagawa M, Hislop A, Boyd EA, Reid L. Lung hypoplasia in congenital diaphragmatic hernia: A quantitative study of airway, artery, and alveolar development. Br J Surg 1971;58:342-6.

21. Cooney TP; Thurlbeck WM. Pulmonary hypoplasia in Down’s syndrome. N Engl J Med 1982;307:1170-3.

22. Cappelli S, Perlman M. Pulmonary hypoplasia: Lung weight and radial alveolar count as criteria of diagnosis. Arch Dis Child 1979;54:614-8.

23. Murphy JD, Vawter GF, Reid LM. Pulmonary vascular disease in fatal meconium aspiration. J Pediatr 1984;104:758-62.

24. Geggel RL, Reid LM. The structural basis of PPHN. Clin Perinatal 1984;11:325-49.

25. Haworth SG, Reid L. Persistent fetal circulation: newly recognized structural features. J Pediatr 1976;88:614-20.

26. Guillot L, Carre A, Szimai G, Castanet M, Tron E, Jaubert F, et al. NKX2 1 mutations leading to surfactant protein promoter dysregulation cause intermittent lung disease in “Brain-Lung-Thyroid Syndrome.” Hum Mutat 2010;31:E1146-62.

27. Boggaram V. Thyroid transcription factor-1 (TTF-1/NKx2.1/TITF1) gene regulation in the lung. Clin Sci (Lond) 2009;116:27-35.

28. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:819-20.

29. Kinsella JP, Abman SH. Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn. J Pediatr 1995;126:853-64.

30. McManus R, Perlman M. Pulmonary hypoplasia: Lung weight and radial alveolar count as criteria of diagnosis. Arch Dis Child 1979;54:614-8.

31. Murphy JD, Vawter GF, Reid LM. Pulmonary vascular disease in fatal meconium aspiration. J Pediatr 1984;104:758-62.

32. Geggel RL, Reid LM. The structural basis of PPHN. Clin Perinatal 1984;11:325-49.

33. Haworth SG, Reid L. Persistent fetal circulation: newly recognized structural features. J Pediatr 1976;88:614-20.

34. Guillot L, Carre A, Szimai G, Castanet M, Tron E, Jaubert F, et al. NKX2 1 mutations leading to surfactant protein promoter dysregulation cause intermittent lung disease in “Brain-Lung-Thyroid Syndrome.” Hum Mutat 2010;31:E1146-62.

35. Boggaram V. Thyroid transcription factor-1 (TTF-1/NKx2.1/TITF1) gene regulation in the lung. Clin Sci (Lond) 2009;116:27-35.

36. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:819-20.

37. Steinhorn RH, Kinsella JP, Pierce C, Butrous G, Oakes M, et al. Intrapulmonary silicosis in neonates with persistent pulmonary hypertension. J Pediatr 2009;155:841-7.e1.

38. Steinhorn RH. Neonatal pulmonary hypertension. Pediatr Crit Care Med 2010;11 Suppl 2:S57-9.

39. Thebaud B, Tiboob D. Pulmonary hypertension associated with congenital diaphragmatic hernia. Cardiol Young 2009;19 Suppl 1:49-53.

40. Kinsella JP, IVY DD, Abman SH. Pulmonary vasodilator therapy in congenital diaphragmatic hernia: Acute, late, and chronic pulmonary hypertension. Semin Perinatol 2005;29:123-8.

41. Chang AC, Macrae D. Neonates with congenital cardiac defects and pulmonary hypertension. Cardiol Young 2009;19 Suppl 1:47-53.

42. Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: A pilot randomized blinded study. Pediatrics 2006;117:1077-83.

43. Peñaloza D, Sime F, Ruiz L, Oakes M, et al. Intrapulmonary silicosis in neonates with persistent pulmonary hypertension. J Pediatr 2009;155:841-7.e1.

44. Steinhorn RH. Neonatal pulmonary hypertension. Pediatr Crit Care Med 2010;11 Suppl 2:S57-9.

45. Thebaud B, Tiboob D. Pulmonary hypertension associated with congenital diaphragmatic hernia. Cardiol Young 2009;19 Suppl 1:49-53.

46. Kinsella JP, IVY DD, Abman SH. Pulmonary vasodilator therapy in congenital diaphragmatic hernia: Acute, late, and chronic pulmonary hypertension. Semin Perinatol 2005;29:123-8.

47. Chang AC, Macrae D. Neonates with congenital cardiac defects and pulmonary hypertension. Cardiol Young 2009;19 Suppl 1:47-53.

48. Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: A pilot randomized blinded study. Pediatrics 2006;117:1077-83.

49. Peñaloza D, Sime F, Ruiz L. Pulmonary hemodynamics in children living at high altitudes. High Alt Med Biol 2008;9:199-207.

50. Díaz G, Márquez A. Hipertensión Pulmonar en Niños a Moderada severidad. In: Díaz G, Sandoval J, Sola A, Cifuentes P, editors. Hipertensión Pulmonar en Niños. Bogotá: Editorial Médica Distribúnia; 2011. p. 266-84.

51. Gamboa R, Martínez A, Llambias A, Cardenas D, Vásquez M, et al. Clinical classification of pediatric pulmonary hypertension. J Pediatr 1992;126:853-64.
Pulmonary Circulation 2011;10(2):296-360

del Cerro et al.: Consensus approach to classification
Type 1 neurofibromatosis complicated by pulmonary artery hypertension: A case report. J Med Invest 2007;54:354-8.

102. Stewart DR, Cogan JD, Kramer MR, Miller WT Jr, Christiansen LE, Paucitol MW, et al. Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy? Chest 2007;132:798-808.

103. Engel PJ, Baughman RP, Menon SC, Kereiakes DJ, Taylor L, Scott M. Pulmonary hypertension in neurofibromatosis. Am J Cardiol 2007;99:1177-8.

104. Aoki Y, Kodama M, Mezaki T, Ogawa R, Sato M, Okabe M, et al. von Recklinghausen disease complicated by pulmonary hypertension. Chest 2008;133:1669-8.

105. Banks S, Newman WG, Ozgur RK, Dursun A. Mutations in the G6PC3 gene cause Dursun syndrome. Am J Med Genet A 2010;152:2609-11.

106. Scurr I, Wilson L, Lees M, Robertson S, Kirk E, Turner A, et al. Cantu syndrome: Report of nine new cases and expansion of the clinical phenotype. Am J Med Genet A 2011;155:508-18.

107. Suzuki K, Yamaki S, Mimori S, Murakami Y, Mori K, Takashashi Y, et al. Pulmonary vascular disease in Down's syndrome with complete atrioventricular septal defect. Am J Cardiol 2000;86:434-7.

108. Matsumura Y, Ban N, Inagaki N. Aberrant calcific pulmonary artery in children from Leadville, Colorado, after recovery from high-altitude pulmonary edema. Circulation 1985;72:957-62.

109. Park SK, Amos L, Rao A, Quasney MW, Matsumura Y, Inagaki N, et al. Identification and characterization of a novel ABCA3 mutation. Physiol Genomics 2010;40:94-9.

110. Bahns PS, Gahunia HK, Massicotte P. Pulmonary thromboembolism in 18 children. Pediatr Radiol 2005;35:258-74.

111. Tavil B, Kusunkoz B, Kiper N, Cetin M, Gumnuk F, Gurgey A. Pulmonary thromboembolism in childhood: A single-center experience from Turkey. Heart Lung 2009;38:56-65.

112. Brandstetter Y, Weinhouse E, Splaingard ML, Tang TT. Cor pulmonale as a pathophysiological entity to different diseases. Eur Respir J 2003;22:1519-25.

113. Staser JA, Alam T, Applegate K. Calcified pulmonary thromboembolism in children. High Alt Med Biol 2003;4:53-9.

114. Yutani C, Imakita M, Ishibashi-Ueda H, Okubo S, Naito M, Kunieda T. Primary pulmonary hypertension in children with congenital portosystemic shunt. J Pediatr 1992;120:320-9.

115. Apathy CW, Krowka MJ, Pham TH, Freee DK, El Youssuf M, Sandor DD. Primary pulmonary arterial hypertension and autoimmune polyendocrine syndrome. Pediatr Radiol 2008;41:892-9.

116. McLaughlin CF, Steinrauf M, Panagiotopoulos C, Potts JE, Sandor DD. Pulmonary arterial hypertension and coexisting portal hypertension in children. J Pediatr 2008;153:187-20.

117. Alghamdi MF, Steinrauf M, Panagiotopoulos C, Potts JE, Sandor DD. Primary pulmonary arterial hypertension and autoimmune polyendocrine syndrome in a pediatric patient. Pediatr Cardiol 2010;31:872-4.

118. Haworth SG, Hislop A, Reid L. Editorial: Progressive pulmonary hypertension in children with portal hypertension. J Pediatr 1974;84:783-5.

119. Newman B, Feinstein JA, Cohen RA, Feingold B, Kreutzer J, Patel H, et al. Congenital extrapulmonary portosystemic shunt associated with heterotaxy syndrome. J Pediatr 2007;143:137-41.

120. Saunders JB, Constable TJ, Heath D, Smith P, Paton A. Pulmonary hypertension complicating portal vein thrombosis. Thorax 1979;34:281-3.

121. Bower JS, Dantzer DK, Naylor B. Idiopathic pulmonary hypertension associated with nodular pulmonary infiltrates and portal venous thrombosis. Chest 1980;78:111-3.

122. Cohen MD, Rubin LJ, Taussig WA, Cuthbert JA. Primary pulmonary hypertension: An unusual case associated with extrapulmonary portal hypertension. Hepatology 1983;3:388-92.

123. Edwards BS, Weir EK, Edwards WD, Ludwig J, Dykoski RK, Edwards JE. Coexistent pulmonary and portal hypertension: morphologic and clinical correlation. J Am Coll Cardiol 2001;37:121-8.

124. Vutani C, Imakita M, Ishibashi-Ueda H, Okubo S, Naito M, Kurida T. Nodular pulmonary hyperplasia in children with associated extrahepatic portal hypertension. Hepatology 2007;45:822-9.

125. Edwards BS, Weir EK, Edwards WD, Ludwig J, Dykoski RK, Edwards JE. Coexistent pulmonary and portal hypertension: morphologic and clinical correlation. J Am Coll Cardiol 2001;37:121-8.

126. Edwards BS, Weir EK, Edwards WD, Ludwig J, Dykoski RK, Edwards JE. Coexistent pulmonary and portal hypertension: morphologic and clinical correlation. J Am Coll Cardiol 2001;37:121-8.

127. Padeh S, Laxer RM, Silver MM, Silverman ED. Primary pulmonary hypertension in a patient with systemic-onset juvenile arthritis. Rheumatology 1991;31:1575-9.

128. Connor P, Veys P, Amrolia P, Haworth S, Ashworth M, Molewina S. Pulmonary hypertension in children with Evans syndrome. Pediatr Hematol Oncol 2008;25:53-8.

129. Nagai H, Yasuma K, Katsuki T, Shimakura A, Usuda K, Nakamura Y, et al. Primary antiphospholipid syndrome and pulmonary hypertension with prolonged survival. A case report. Angiology 1997;48:183-7.

130. Fabrisno G, Cervena B, Font J, Asherson RA. The lung in the antiphospholipid syndrome. Ann Rheum Dis 2002;61:195-8.

131. Sharma S, Kirpalani A, Downie J, Turner A, Paton A. Pulmonary hypertension associated with congenital left atrial isomerism and atrial septal defect. J Am Coll Cardiol 2001;38:1073-80.

132. Naborji P, Putterman A, Knopp T, Bentley MG, McDonald R, Segerman J. Pulmonary hypertension in a young patient with end-stage renal disease on chronic hemodialysis. Pediatr Cardiol 2010;31:184-6.

133. Yigla M, Nakhoul F, Sabag A, Tov N, Gorevich B, Abassi Z, et al. Pulmonary hypertension in patients with end-stage renal disease. Pediatr Cardiol 2003;24:1577-82.
153. Unal A, Sipahioglu M, Oğuz F, Kaya M, Kucuk H, Tokgoz B, et al. Pulmonary hypertension in peritoneal dialysis patients: Prevalence and risk factors. Perit Dial Int 2009;29:191-8.

154. Amin M, Fawzy A, Hamid MA, Elhendy A. Pulmonary hypertension in patients with chronic renal failure: Role of parathyroid hormone and pulmonary artery calcifications. Chest 2003;124:2093-7.

155. Havlucu Y, Kursat S, Ekmekci C, Celik P, Serter S, Bayturk O, et al. Pulmonary hypertension in patients with chronic renal failure. Respiration 2007;74:903-10.

156. Adatia I. Pulmonary veno-occlusive disease. In: Freedom RM, Yoo SJ, Mikailian H, Williams WG, editors. The natural and modified history of congenital heart disease. New York: Futura; 2004. p. 513.

157. Kobayashi D, Cook, A, Williams D. Pulmonary hypertension secondary to partial pulmonary venous obstruction in a child with Cantù syndrome. Pediatr Radiol 2010;45:727-9.

158. Gewillig M, Brown SC, De Catte L, Debeer A, Eyskens B, Cossey V, et al. Premature foetal closure of the arterial duct: Clinical presentations and outcome. Eur Heart J 2009;30:1530-6.

159. Van Marter LJ, Leivoton A, Allred EN, Pagano M, Sullivan KE, Cohen A, et al. Persistent pulmonary artery hypertension of the newborn and smoking and aspirin and nonsteroidal anti inflammatory drug consumption during pregnancy. Pediatrics 1996;97:658-63.

160. Siu KL, Lee WH. Maternal diclofenac sodium ingestion and severe neonatal pulmonary hypertension. J Pediatr Child Health 2004;40:152-3.

161. Schiessl B, Schneider KT, Zimmerman A, Kainer F, Friese K, Oberhoffer R. Prenatal constriction of the fetal ductus arteriosus-related to maternal pain medication? Z Geburtshilfe Neonatol 2005;209:65-8.

162. Alano MA, Ngoumna E, Ostrea EM Jr, Konduri GG. Analysis of nonsteroidal anti-inflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 2001;107:519-23.

163. Zender M, Klinge J, Kruger C, Singer H, Scharf J. Severe pulmonary hypertension in a neonate caused by premature closure of the ductus arteriosus following maternal treatment with diclofenac: A case report. J Perinat Med 1998;26:231-4.

164. Mas C, Menahem S. Premature in utero closure of the ductus arteriosus following maternal ingestion of sodium diclofenac. Aust N Z J Obstet Gynaecol 1999;39:106-7.

165. Talati AJ, Salim MA, Korones SB. Persistent pulmonary hypertension after maternal naproxen ingestion in a term newborn: A case report. Am J Perinatol 2000;17:69-71.

Source of Support: Nil, Conflict of Interest: None declared

Author Institution Mapping (AIM)

Please note that not all the institutions may get mapped due to non-availability of the requisite information in the Google Map. For AIM of other issues, please check the Archives/Back Issues page on the journal’s website.